1. Home
  2. SAGE
  3. SAGE News

Latest Sage Therapeutics Inc. (SAGE) News on December 22, 2024

Sage Therapeutics price target lowered to $6 from $10 at Stifel
SAGE

TipRanks

5 days ago

Sage Therapeutics price target lowered to $6 from $10 at Stifel

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
SAGE

Business Wire

a month ago

Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Sage Therapeutics price target lowered to $4 from $7 at BofA
SAGE

TipRanks

a month ago

Sage Therapeutics price target lowered to $4 from $7 at BofA

SAGE

MT Newswires

a month ago

Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
SAGE

Zacks

a month ago

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

Sage ends dalzanemdor development following Phase II trial failure
SAGE

Clinical Trials Arena

a month ago

Sage ends dalzanemdor development following Phase II trial failure

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
SAGE

Zacks

a month ago

SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
SAGE

Benzinga

a month ago

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

SAGE

MT Newswires

a month ago

Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating

SAGE

MT Newswires

a month ago

SAGE Therapeutics' Study of Dalzanemdor Fails to Meet Primary, Secondary Endpoints

Sage’s string of research failures continues
SAGE

BioPharma Dive

a month ago

Sage’s string of research failures continues

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
SAGE

Business Wire

a month ago

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler
SAGE

TipRanks

2 months ago

Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
SAGE

Zacks

2 months ago

SAGE's Q3 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Biogen, Sage admit a defeat in major depression
SAGE

BioPharma Dive

2 months ago

Biogen, Sage admit a defeat in major depression

Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
SAGE

GuruFocus.com

2 months ago

Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates
SAGE

Zacks

2 months ago

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
SAGE

Business Wire

2 months ago

Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
SAGE

Zacks

2 months ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
SAGE

Zacks

2 months ago

Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

State Street Corp's Strategic Acquisition of Sage Therapeutics Shares
SAGE

GuruFocus.com

2 months ago

State Street Corp's Strategic Acquisition of Sage Therapeutics Shares

Sage Therapeutics to Reduce Workforce by 33%, Stock Down
SAGE

Zacks

2 months ago

Sage Therapeutics to Reduce Workforce by 33%, Stock Down

Sage lays off 55% of R&D workforce and refocuses pipeline
SAGE

Pharmaceutical Technology

2 months ago

Sage lays off 55% of R&D workforce and refocuses pipeline

Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
SAGE

GuruFocus.com

2 months ago

Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
SAGE

Benzinga

2 months ago

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce

Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
SAGE

Barrons.com

2 months ago

Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.

Sage to cut one-third of workforce, streamline drug pipeline
SAGE

BioPharma Dive

2 months ago

Sage to cut one-third of workforce, streamline drug pipeline

SAGE

MT Newswires

2 months ago

SAGE Therapeutics to Cut Workforce by 33%, or 165 Workers, in Reorganization

Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
SAGE

Business Wire

2 months ago

Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
SAGE

Business Wire

2 months ago

Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Sage Therapeutics price target lowered to $8 from $9 at Wedbush
SAGE

TipRanks

2 months ago

Sage Therapeutics price target lowered to $8 from $9 at Wedbush

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
SAGE

Zacks

2 months ago

SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study

Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment
SAGE

Barrons.com

2 months ago

Sage Therapeutics Reports Disappointing Study Results for Alzheimer’s Treatment

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
SAGE

Benzinga

2 months ago

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study

SAGE

MT Newswires

2 months ago

Sector Update: Health Care

Sage continues downslide as Alzheimer’s study fails
SAGE

BioPharma Dive

2 months ago

Sage continues downslide as Alzheimer’s study fails

Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
SAGE

Barrons.com

2 months ago

Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment

SAGE

Investing.com

2 months ago

Sage Therapeutics stock drops after disappointing Alzheimer's trial results

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
SAGE

Business Wire

2 months ago

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease

Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
SAGE

Zacks

2 months ago

Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why

SAGE

MT Newswires

3 months ago

Sector Update: Health Care Stocks Steady Late Afternoon

SAGE

MT Newswires

3 months ago

Sector Update: Health Care Stocks Softer Friday Afternoon

SAGE

Investing.com

3 months ago

Sage stock slides as RBC cuts rating to Sell on trial results concerns

SAGE

MT Newswires

3 months ago

Sage Therapeutics Faces High-Risk Outlook Amid Concerns Over Success in Phase 2 Huntington's Disease Trial, RBC Says

SAGE

MT Newswires

3 months ago

RBC Downgrades Sage Therapeutics to Sector Perform From Outperform, Adjusts Price Target to $4 From $10

Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now
SAGE

Insider Monkey

3 months ago

Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
SAGE

Zacks

3 months ago

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends
SAGE

TipRanks

3 months ago

SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
SAGE

Benzinga

3 months ago

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate

SAGE

MT Newswires

3 months ago

Sage Therapeutics Says Biogen Discontinues Collaboration on Sage-324 Program

Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
SAGE

Business Wire

3 months ago

Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program

Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers
SAGE

Insider Monkey

3 months ago

Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers

SAGE

MT Newswires

3 months ago

Sage Therapeutics Files Registration Statement for Planned Mixed-Shelf Offering

Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?
SAGE

Zacks

4 months ago

Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?

SAGE

MT Newswires

4 months ago

Truist Adjusts Price Target on Sage Therapeutics to $13 From $18, Maintains Hold Rating

Analysts Have Been Trimming Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target After Its Latest Report
SAGE

Simply Wall St.

5 months ago

Analysts Have Been Trimming Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target After Its Latest Report

Sage Therapeutics Second Quarter 2024 Earnings: Misses Expectations
SAGE

Simply Wall St.

5 months ago

Sage Therapeutics Second Quarter 2024 Earnings: Misses Expectations

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
SAGE

Zacks

5 months ago

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
SAGE

Zacks

5 months ago

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
SAGE

Business Wire

5 months ago

Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
SAGE

Zacks

5 months ago

Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates

SAGE

MT Newswires

5 months ago

TD Cowen Downgrades Sage Therapeutics to Hold From Buy, Adjusts Price Target to $10 From $16

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
SAGE

Zacks

5 months ago

The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical

SAGE

MT Newswires

5 months ago

Baird Adjusts Price Target on Sage Therapeutics to $13 From $15, Maintains Neutral Rating

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
SAGE

Zacks

5 months ago

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?

SAGE

MT Newswires

5 months ago

Morgan Stanley Halves Price Target on Sage Therapeutics to $11 From $22, Keeps Equalweight Rating

SAGE

MT Newswires

5 months ago

JPMorgan Downgrades Sage Therapeutics to Neutral From Overweight, Adjusts Price Target to $12 From $18

Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
SAGE

Clinical Trials Arena

5 months ago

Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
SAGE

Investor's Business Daily

5 months ago

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails

SAGE

MT Newswires

5 months ago

Sage Therapeutics, Biogen Stop Development of Investigational Drug for Essential Tremor

Sage Therapeutics Stock Slides as Pipeline Thins
SAGE

Barrons.com

5 months ago

Sage Therapeutics Stock Slides as Pipeline Thins

SAGE

MT Newswires

5 months ago

Wedbush Adjusts Sage Therapeutics' PT to $9 From $15, Maintains Neutral Rating

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SAGE

Zacks

5 months ago

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Biogen, Sage tremor drug fails key trial
SAGE

BioPharma Dive

5 months ago

Biogen, Sage tremor drug fails key trial

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
SAGE

Business Wire

5 months ago

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment
SAGE

Clinical Trials Arena

5 months ago

Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
SAGE

Zacks

5 months ago

SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern

SAGE

MT Newswires

5 months ago

Mizuho Securities Lowers Adjusts Price Target on Sage Therapeutics to $16 From $18, Maintains Neutral Rating

Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
SAGE

Business Wire

5 months ago

Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

SAGE

MT Newswires

5 months ago

JPMorgan Lowers Price Target on Sage Therapeutics to $18 From $23, Maintains Overweight Rating

SAGE

MT Newswires

5 months ago

RBC Cuts Price Target on Sage Therapeutics to $12 From $15, Keeps Sector Perform Rating

SAGE

MT Newswires

6 months ago

JPMorgan Adjusts Price Target on Sage Therapeutics to $23 From $28, Maintains Overweight Rating

SAGE's Huntington's Disease Study Meets Primary Endpoint
SAGE

Zacks

6 months ago

SAGE's Huntington's Disease Study Meets Primary Endpoint

SAGE

MT Newswires

6 months ago

Sage Therapeutics Says Phase 2 SURVEYOR Trial Met Primary Endpoint

Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
SAGE

Business Wire

6 months ago

Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
SAGE

GOBankingRates

6 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
SAGE

Business Insider

6 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women
SAGE

Insider Monkey

6 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
SAGE

Reuters

6 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

SAGE

Insider Monkey

6 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow
SAGE

AFP

6 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events
SAGE

Investor's Business Daily

6 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments
SAGE

The Wall Street Journal

6 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.
SAGE

ACCESSWIRE

6 months ago

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.

Intermediate Capital Group plc: Notification of Transactions of Directors
SAGE

GlobeNewswire

6 months ago

Intermediate Capital Group plc: Notification of Transactions of Directors

Lyft stock earns multiple upgrades after investor day
SAGE

Yahoo Finance Video

6 months ago

Lyft stock earns multiple upgrades after investor day

Finally, I can make my iPhone look like total crap
SAGE

Engadget

6 months ago

Finally, I can make my iPhone look like total crap

Intermediate Capital Group plc: Vesting in Share Awards/ Notification of Transactions of Directors
SAGE

GlobeNewswire

6 months ago

Intermediate Capital Group plc: Vesting in Share Awards/ Notification of Transactions of Directors

Stock Split Watch: 3 Growth Stocks That Could Be Next
SAGE

Motley Fool

6 months ago

Stock Split Watch: 3 Growth Stocks That Could Be Next

Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers
SAGE

PR Newswire

6 months ago

Tsingke Concludes a Successful Showcase at TIDES USA 2024: Advancing Biotechnology Frontiers

Share on Social Networks: